Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective observational study of dotinurad in hyperuricemic patients with impaired renal function
jRCT1051230149Completed
- Sponsor
- Shimazu keiji
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dotinurad in hyperuricemia and chronic kidney disease (CKD), sponsored by Shimazu keiji. Primary endpoint: Proportion with serum uric acid ≤6.0 mg/dL at 12 months. Started Dec 2023; status: completed.
02
Drugs
dotinurad
03
Conditions
hyperuricemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT1051230149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051230149.